---
title: "DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development"
date: "2025-02-13 14:00:57"
summary: "DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development PR Newswire SEOUL, South Korea, Feb. 13, 2025 SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics,..."
categories:
  - "morningstar"
lang:
  - "en"
translations:
  - "en"
tags:
  - "morningstar"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development

DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
-----------------------------------------------------------------------------------------------------------------------------------------------------

PR Newswire

SEOUL, South Korea, Feb. 13, 2025


SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).

[![](https://mma.prnewswire.com/media/2619322/250212.jpg)](https://mma.prnewswire.com/media/2619322/250212.html)

By leveraging DAAN Biotherapeutics' next-generation antibody technology, built upon its exceptional target discovery and antibody development capabilities, LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.

DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.

Byoung Chul Cho, MD, the CEO of DAAN Biotherapeutics, stated, "We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs, we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform."

 ![](https://c212.net/c/img/favicon.png?sn=CN18545&sd=2025-02-13) View original content to download multimedia:<https://www.prnewswire.com/news-releases/daan-biotherapeutics-signs-antibody-exclusive-licensing-agreement-with-ligachem-biosciences-for-adc-antibody-drug-conjugate-therapeutic-development-302375629.html>

SOURCE DAAN Biotherapeutics

[morningstar](https://www.morningstar.com/news/pr-newswire/20250213cn18545/daan-biotherapeutics-signs-antibody-exclusive-licensing-agreement-with-ligachem-biosciences-for-adc-antibody-drug-conjugate-therapeutic-development)
